Raxibacumab: potential role in the treatment of inhalational anthrax.

Infect Drug Resist · 2014 · PMC4011807 · PMID 24812521

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

33 Although the difference in survival rate did not reach statistical significance, it was higher in the group that received the combination of levofloxacin and raxibacumab.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.